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Introduction: In this study, we planned to assess if adult stem cell-based suicide gene therapy can efficiently
eliminate glioblastoma cells in vivo. We investigated the therapeutic potential of mouse Oct4− bone marrow
multipotent adult progenitor cells (mOct4− BM-MAPCs) in a mouse glioblastoma model, guided by multimodal
in vivo imaging methods to identify therapeutic windows.
Methods: Magnetic resonance imaging (MRI) of animals, wherein 5 × 105 syngeneic enhanced green fluorescent
protein-firefly luciferase-herpes simplex virus thymidine kinase (eGFP-fLuc-HSV-TK) expressing and
superparamagnetic iron oxide nanoparticle labeled (1 % or 10 %) mOct4− BM-MAPCs were grafted in glioblastoma
(GL261)-bearing animals, showed that labeled mOct4− BM-MAPCs were located in and in close proximity to the
tumor. Subsequently, ganciclovir (GCV) treatment was commenced and the fate of both the MAPCs and the tumor
were followed by multimodal imaging (MRI and bioluminescence imaging).
Results: In the majority of GCV-treated, but not phosphate-buffered saline-treated animals, a significant difference
was found in mOct4− BM-MAPC viability and tumor size at the end of treatment. Noteworthy, in some phosphate-
buffered saline-treated animals (33 %), a significant decrease in tumor size was seen compared to sham-operated
animals, which could potentially also be caused by a synergistic effect of the immune-modulatory stem cells.
Conclusions: Suicide gene therapy using mOct4− BM-MAPCs as cellular carriers was effective in reducing the
tumor size in the majority of the GCV-treated animals leading to a longer progression-free survival compared to
sham-operated animals. This treatment could be followed and guided noninvasively in vivo by MRI and
bioluminescence imaging. Noninvasive imaging is of particular interest for a rapid and efficient validation of stem
cell-based therapeutic approaches for glioblastoma and hereby contributes to a better understanding and
optimization of a promising therapeutic approach for glioblastoma patients.Introduction
Gliomas arise from glial cells (astrocytes, oligodendrogial
and ependymal cells) and are the most common brain
tumors in humans. They comprise a broad range of le-
sions with distinct differences in malignancy, which is
classified according to the World Health Organization
(WHO) [1]. Glioblastoma multiforme (GBM) are the
most malignant tumors (WHO grade IV) in the* Correspondence: Uwe.Himmelreich@med.kuleuven.be
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diagnosed with GBM is still extremely poor, with a 5-
year survival of less than 3 % of patients despite multi-
modal treatment approaches consisting of surgery and
concomitant radio- and chemotherapy [3]. Therefore,
new treatment modalities are under investigation, among
which is therapy based on the bystander killing effect
following suicide gene therapy as has been tested in the
past [4–8].
This therapeutic approach relies on administration of
cells carrying a suicide gene, such as the gene encoding
for the herpes simplex virus-thymidine kinase (HSV-
TK). When the substrate for this enzyme is provided, foris distributed under the terms of the Creative Commons Attribution 4.0
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verted by HSV-TK into GCV-monophosphate. The
HSV-TK displays a 1000-fold higher affinity for GCV
than the mammalian TK and therefore this targeting ap-
proach limits systemic toxicity while the increased affin-
ity boosts tumor therapy capabilities [9]. Subsequently,
cellular kinases recognize the GCV-monophosphate and
will create GCV-triphosphate, a guanine nucleoside
analogue which causes DNA chain termination and sub-
sequent cell death. Due to the formation of gap junc-
tions between adjacent cells, GCV-monophosphate can
passively diffuse into neighboring cells which will result
in mostly tumor and therapeutic cell killing, as normal
adult brain cells usually do not replicate [10]. This is also
known as ‘the bystander killing effect’. Previously, at-
tempts were tested in clinical trials to treat glioblastoma
patients using viral vectors encoding for HSV-TK by dir-
ectly introducing the suicide gene into tumor cells, with
usually poor results [11]. This is generally believed to be
caused by insufficient distribution of the viral vectors
throughout the tumor [12]. Therefore, attention turned
to carriers such as bacteria [13, 14] and tumor-tracking
stem cells [15] to enhance delivery of the suicide gene.
Stem cells that are capable of forming gap junctions with
infiltrating tumor cells would allow transfer of the GCV-
phosphate into neighboring cells, which results in
bystander-mediated tumor cell killing [16, 17]. This ap-
proach can in theory eliminate both the primary tumor
and the infiltrating tumor cells, thus eliminating sources
of possible recurrent tumors [9].
The feasibility of this strategy was demonstrated by
several groups in both xenograft and syngeneic animal
models [5, 6, 9, 18–20]. Miletic et al. [9] and Matuskova
et al. [21] demonstrated a potent bystander killing effect
of HSV-TK expressing rat bone marrow (BM)-derived
tumor-infiltrating progenitor cells on 9 L rat gliomas
and human mesenchymal stem cells (hMSCs) on the hu-
man glioblastoma cell lines 8-MG-BA, 42-MG-BA and
U-118 MG.
In previous reports, different imaging modalities have
been used mainly for the assessment of the treatment ra-
ther than for guidance of therapy [18]. In a clinical setting,
patients are routinely followed up by noninvasive imaging
such as magnetic resonance imaging (MRI) and positron
emission tomography (PET) [22, 23]. In a preclinical set-
ting, these noninvasive imaging techniques are also avail-
able and should therefore, when possible, also be used to
guide therapy and evaluate treatment response. Further-
more, additional preclinical imaging modalities such as
bioluminescence imaging (BLI) are available to further
optimize the acquired information prior to treatment initi-
ation and follow-up of therapeutic efficacy [24]. In
addition, molecular imaging methods could also be used
to monitor the location of therapeutic cells [25].We have shown previously that mouse Oct4− BM-
derived multipotent adult progenitor cells (mOct4−
BM-MAPCs) are safe for in vivo applications and are
responsive to GCV in the healthy mouse brain as
assessed by BLI [26]. In this study, we intended to as-
sess the therapeutic potential of mOct4− BM-MAPCs
in a mouse glioblastoma model and, in particular, the
guidance of therapy by cellular imaging methods for
optimization of the therapeutic response and for the
identification of therapeutic windows. For instance,
MRI in combination with superparamagnetic iron oxide
(SPIO) particles or BLI in combination with Firefly lu-
ciferase (fLuc)-expressing cells can provide information
on the location and/or function of cells. The GL261
model was used, which is a mouse glioblastoma model
in a syngeneic (immunocompetent) host that has been
characterized extensively [27, 28] and is widely consid-
ered as the gold standard in glioblastoma research.
Materials and methods
Cells
Cell culture
mOct4− BM-MAPCs were obtained from the Stem Cell
Institute at KU Leuven. Cells were cultured as described
previously [29]. In short, dishes coated with fibronectin
were used when splitting the cells every 48 hours.
Medium contained 60 % low-glucose Dulbecco’s modified
Eagle medium (DMEM; Gibco BRL, Sigma-Aldrich, St.
Louis, MO, USA), 40 % MCDB-201 (Sigma-Aldrich), 1 ×
selenium-insulin-transferrin-ethanolamine (ITS; Sigma-
Aldrich), 0.2 mg/ml LA-BSA and 0.8 mg/mL powdered
bovine serum albumin (BSA; Sigma-Aldrich), 10−4 M as-
corbic acid 3-phosphate (Sigma-Aldrich), 100 units of
penicillin, 1000 units of streptomycin (Gibco®, Invitrogen,
Carlsbad, CA, USA), 2 % fetal bovine serum (Gibco®, Invi-
trogen), 10 ng/mL human platelet-derived growth factor
(R&D systems, Minneapolis, MN, USA), 10 ng/mL mouse
epidermal growth factor (Sigma-Aldrich), 1000 units/ml
mouse leukemia inhibitory factor (Esgro®, Millipore, Biller-
ica, MA, USA) and 1 × chemically defined lipid concen-
trate (Gibco®, Invitrogen). Finally, β-mercaptoethanol (1 ×;
Gibco®, Invitrogen) was added freshly to the media before
sterilization with a 22-mm filter (Millipore).
The GL261 cell line, extensively used in mouse
models of glioblastoma, was obtained from Dr S. Van
Gool, KU Leuven. GL261 cells were cultured as de-
scribed earlier [30].
Transduction
mOct4− BM-MAPCs were consecutively transduced
(p24 = 20 pg p24/cell) with two lentiviral vectors with
an EF1α promoter [26]. The first transfer plasmid was
engineered to express a 3×flag tagged fLuc (3flag-fLuc)
together with HSV-TK and a blasticidin resistance
Leten et al. Stem Cell Research & Therapy  (2015) 6:163 Page 3 of 13cassette (BsdR) linked by a peptide2A sequence (T2A)
and an internal ribosomal entry site (IRES), respect-
ively (pCH-EF1a-3flag-fLuc-T2A-HSV-TK-IRES-BsdR).
The second transfer plasmid encoded enhanced green
fluorescent protein (eGFP) and a puromycin resistance
cassette (PuroR), linked by an IRES (pCH-EF1a-eGFP-
IRES-PuroR). The lentiviral vectors are referred to as
LV_ EF1a-3flag-fLuc-T2A-HSV-TK-IRES-BsdR and
LV_EF1a-eGFP-IRES-PuroR, respectively. mOct4− BM-
MAPCs were consecutively transduced (p24 = 20 pg
p24/cell) with both lentiviral vectors.
First, LV_EF1a-eGFP-IRES-PuroR was used for trans-
duction. Subsequently, cells were selected with puro-
mycin (2–4 μg/ml; Sigma-Aldrich). Following selection,
LV_ EF1a-3flag-fLuc-T2A-HSV-TK-IRES-BsdR was used
to transduce these cells, which were subsequently se-
lected with blasticidin (20–80 μg/ml; Invivogen, San
Diego, USA).
In vitro validation of cell labeling with SPIO particles
mOct4− BM-MAPCs were labeled for 24 hours with ei-
ther Endorem® (Guerbet, Roissy, France) or with in-
house-produced SPIO particles (ihSPIO; 20 μg iron/ml)
in combination with poly-L-lysin (1.5 μg/ml) (see SMG2-
mPEGSi nanoparticles in [31] for the properties of the
ihSPIO) [31, 32]. Subsequently, cells were washed three
times and kept overnight in fresh medium after which
1 × 105 cells were harvested for MRI and 5 × 104 were
harvested for induced coupled plasma-optical emis-
sion spectroscopy (ICP-OES) measurements (for more
details, see also [31, 32]). MRI phantoms containing 500
cells/μl were prepared to validate MRI detectability limits.
In vitro T2* MR images were acquired (parameters:
multigradient echo pulse sequence, repetition time
(TR) = 1500 ms, first echo time (TE) = 4.44 ms with 8
increments of 6.75 ms, matrix size = 400 × 400, in
plane resolution = 18.7 μm2, slice thickness = 0.35 mm,
number of slices = 12).
In vivo models
Stereotactical tumor and/or stem cell injections
All animal experiments were conducted according to the
European Union Community Council guidelines and
were approved by the Animal Ethics Committee of the
KU Leuven. Before surgery, animals were anaesthetized
by an intraperitoneal injection with a mixture of keta-
mine (Ketamine1000, 4.5 mg/kg; Ceva, Pompidou,
France)/medetomidin (Domitor®, 0.6 mg/kg; Pfizer, New
York, USA). Local analgesia (2 % xylocain; AstraZeneca,
London, UK) and antibiotics (6 mg/mouse, Ampiveto-
20, 200 mg/ml; VMD, New Haw, Surrey, UK) were ad-
ministered prior to surgery. After fixation of the animals
in a stereotactic frame adapted with a stereotaxic in-
jector (both from Stoelting, Wood Dale, USA), cells weresuspended in 5 μl phosphate-buffered saline (PBS) and
injected (0.5 μl/min) with a 10 μl Hamilton syringe,
equipped with a 22 G needle, into the right striatum of
C57Bl6/j mice at the following coordinates: 0.5 mm an-
terior and 2.0 mm lateral to bregma at 3.0 mm from the
dura.
In vivo assessment of mOct4− BM-MAPCs SPIO labeling
100 % Endorem®- or ihSPIO-labeled cells were injected
stereotactically in the striatum of C57BL6/J mice to as-
sess their detectability in vivo using MRI. For this, PBS,
3 × 105 nonlabeled, 1 × 105 and 3 × 105 Endorem®-la-
beled, as well as 1 × 105 and 3 × 105 ihSPIO-labeled
mOct4− BM-MAPCs, were stereotactically injected (n =
2 for each condition) and monitored using MRI until
day 8 postinjection.
Glioblastoma mouse model (GL261): suicide gene therapy
GL261 (2.5 × 105) were stereotactically injected in the
striatum of C57BL6/j mice and allowed to grow for 2
weeks prior to intratumoral stereotactical injection of 5 ×
105 labeled and transduced mOct4− BM-MAPCs [27].
Two weeks after tumor induction, animals were arbi-
trarily divided into three groups: (1) sham-operated ani-
mals, which received a PBS injection, (2) animals that
were treated with PBS after receiving 5 × 105 mOct4−
BM-MAPCs, and (3) animals that were treated with
GCV after receiving 5 × 105mOct4− BM-MAPCs. To
reduce the blooming effect on T2*-weighted MRI,
which would mask anatomical details in the MRI, only 1
or 10 % of the injected mOct4− BM-MAPCs were labeled
with SPIO particles. Weekly MR imaging was performed
in addition to imaging before and after mOct4− BM-
MAPC injection. BLI was performed following mOct4−
BM-MAPC injection. Treatment (GCV (50 mg/kg) or
PBS) was administered for 14 consecutive days starting at
day 1 post-mOct4− BM-MAPC injection. At the end of
PBS/GCV administration, both MRI and BLI were per-
formed to assess tumor response and mOct4− BM-MAPC
viability, respectively. Animals responding to treatment
were defined as animals with tumors at the end of GCV
treatment that were not significantly larger than at the be-
ginning of the treatment (<5 mm3). Some animals were
followed up after the end of treatment for progression-
free survival analysis. Two GCV-treated animals were
followed for 184 days without tumor re-growth after
which animals were sacrificed. A progression-free survival
analysis was performed. For all other experiments, the
number of animals used per group is stated in the respect-
ive figure legends.
Humane endpoints
Animals were sacrificed when symptoms reached grade
3 out of 4 (grade 0 for healthy mice, grade 1 for slight
Leten et al. Stem Cell Research & Therapy  (2015) 6:163 Page 4 of 13unilateral paralysis, grade 2 for moderate unilateral par-
alysis and/or beginning hunchback, grade 3 for severe
unilateral or bilateral paralysis and pronounced hunch-
back, and grade 4 for moribund mice) according to [33].
In vivo imaging
MRI
All MR images were acquired with a 9.4 T Biospec small
animal MR scanner (Bruker Biospin, Ettlingen, GE)
equipped with a horizontal bore magnet and an actively
shielded gradient set of 600mT m−1 (117 mm inner
diameter) using a 7 cm linearly polarized resonator for
transmission and an actively decoupled dedicated mouse
surface coil for receiving (Rapid Biomedical, Rimpar,
Germany). MRI was performed after GL261 tumor in-
duction, prior (day 14 post-glioblastoma injection) and
following stem cell injection but before treatment initi-
ation (day 16 post-glioblastoma injection) and at the end
of the treatment (day 30 post-glioblastoma injection).
Mice were anesthetized with 2 % isoflurane in oxygen
for induction prior to scanning and with 1.5 % isoflurane
in oxygen for maintenance of anesthesia. Temperature
and respiration were monitored throughout the experi-
ment and maintained at 37 °C and 100–120 breaths/mi-
nute, respectively. For in vivo tracking of the SPIO-labeled
mOct4− BM-MAPCs, three-dimensional T2*-weighted
MR images were acquired (parameters: 3D FLASH se-
quence, TR = 100 ms, TE = 12 ms, flip angle = 20°, iso-
tropic resolution = 78 μm3, field of view = 2.0 × 1.5 × 0.75
cm) and analyzed with the Image J software (National
Institute of Health, Bethesda, Maryland, USA) using a
semi-automated method to calculate the hypointense
pixel volume. Furthermore, two-dimensional T2-weighted
MR images (parameters: axial orientation, RARE se-
quence, TR = 3157.6 ms, TE = 48.8 ms, matrix size =
256 × 256, FOV = 2.5 × 2.5 cm, in plane resolution =
78 μm2, number of slices = 24, slice thickness = 0.5
mm) and MRI scans in coronal orientation (parameters:
RARE sequence, TR = 3000 ms, TE = 50.2 ms, matrix
size = 256 × 256, FOV = 2.5 × 2.5 cm, number of slices =
16, slice thickness = 0.5 mm, in plane resolution = 78
μm2) were acquired to follow-up the tumor size. The area
of the lesion was determined by outlining it manually on
all slices using the Paravision software (Version 5.1, Bru-
ker Biospin). The sum of the cross-sectional area was used
to determine the total tumor size.
BLI
Mice were anesthetized with isoflurane (2 % induction,
1.5 % maintenance) in oxygen and placed in the IVIS® 100
imaging system (Perkin Elmer, Waltham, MA, USA). The
body temperature was maintained at 37 °C throughout the
experiment. D-Luciferin (126 mg/kg in PBS; Promega)
was injected intravenously and bioluminescent imageswere acquired. Data were analyzed for maximum intensity
of the photon flux by the living image® 2.50.1 software
(Perkin Elmer).
Histology
Animals were sacrificed by an intraperitoneal overdose
of nembutal (300 μl; Ceva). They were subsequently per-
fused with a 4 % ice-cold paraformaldehyde (PFA) solu-
tion in PBS (Sigma-Aldrich). After overnight post-
fixation in 4 % PFA, the brain tissue was stored in a 0.1
% sodium azide solution in PBS (Fluka; Sigma-Aldrich)
at 4 °C. Paraffin sections (5 μm) were sliced and a Mas-
son trichrome, a Prussian blue staining and an Iba1
staining were performed [31]. For the latter, sections
were stained with an Iba1 antibody (1/250). Visualization
was achieved using the Dako EnVision + system-HRP
(DAB) kit (Dako, Glostrup, Denmark).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
(GraphPad Software PRISM, La Jolla, CA, USA). Signifi-
cant differences between GCV- and PBS-treated animals
regarding total tumor volumes (MRI; mm3) and cell via-
bility (BLI; P/s) were determined by means of an analysis
of variance test with differences of p < 0.05 regarded sig-
nificant. Figures show mean ± standard error of the
mean (SEM).
Results
In vitro assessment of SPIO labeling of eGFP-fLuc-HSV-TK-
expressing mOct4− BM-MAPCs
eGFP-fLuc-HSV-TK-expressing mOct4− BM-MAPCs
[26] were labeled with ihSPIO particles [31] or Endorem®
after which characterization was performed using ICP-
OES, MRI and BLI (Fig. 1). ICP-OES (Fig. 1a) showed an
iron uptake of 15.9 ± 1.5 pg iron/cell for ihSPIO-labeled
cells compared to 8.2 ± 0.6 pg iron/cell for Endorem®-la-
beled cells. Using optimized labeling conditions, in vitro
cell labeling with ihSPIO-labeled cells showed high con-
trast (low signal intensity) on MRI (Fig. 1b) and no
marked differences in cell viability when comparing la-
beled and unlabeled cells as assessed by BLI (Fig. 1c).
Considering that only 1–2 pg iron are needed for cell
imaging, these results indicate that, for both contrast
agents, single cell visualization in vitro is in principle
feasible and safe [34].
In vivo assessment of mOct4− BM-MAPCs SPIO labeling
Next, we compared the contrast generated by mOct4−
BM-MAPCs labeled with ihSPIO particles or Endorem®
in vivo. For this, 3 × 105 nonlabeled, 1 × 105 and 3 × 105
Endorem®-labeled, as well as 1 × 105 and 3 × 105
ihSPIO-labeled mOct4− BM-MAPCs were injected into
the striatum of C57BL6/j mice after which MRI was
Fig. 1 In vitro validation of SPIO labeling of mOct4− BM-MAPCs. a ICP-OES data showed superior labeling of mOct4− BM-MAPCs using ihSPIO
particles compared to labeling using Endorem® with unlabeled cells containing 1.3 ± 0.8 pg Fe/cell, ihSPIO-labeled mOct4- BM-MAPCs
containing 15.9 ± 1.5 pg Fe/cell and Endorem®-labeled mOct4− BM-MAPCs 8.2 ± 0.6 pg Fe/cell. b An MRI phantom confirmed these results
and showed the corresponding in vitro contrast generation caused by the presence of iron in the cells with enhanced signal decay corresponding to
higher concentrations of iron/cell. c BLI using D-Luciferin as a substrate indicated no marked differences in cell viability between labeled and unlabeled
cells. SMG2-mPEGSI second seed mediated growth-mPolyethylene glycol
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could be detected in vivo on day 2 and day 8 (Fig. 2a)
postinjection, with only a slight decrease in contrast
from day 2 to day 8 as indicated in Fig. 2a. Three hun-
dred thousand ihSPIO-labeled cells generated a more
extensive hypointense contrast compared to mOct4−
BM-MAPCs that were labeled with the same amount of
Endorem®, indicating that contrast generation with
ihSPIO was superior for in vivo cell detection. Masson’s
Trichrome and Prussian blue stainings were performed
on paraffin sections to confirm the presence of the
SPIO particles. The Prussian blue staining confirmed
the presence of iron (Fig. 2b) in areas corresponding to
the location of hypointense signal in MRI. Both con-
trast agents generate sufficient contrast to visualize the
location of engrafted cells for at least 1 week. Due to its
superior imaging properties, cells were labeled with
ihSPIO for all subsequent studies.
In vivo suicide gene therapy using eGFP-fLuc-HSV-TK (+),
ihSPIO-labeled mOct4− BM-MAPCs in a mouse glioblastoma
model
We have previously shown that HSV-TK containing
mOct4− BM-MAPCs can be killed in vitro using GCV
concentrations as low as 0.01 μM [26]. Furthermore, we
have also shown that mOct4− BM-MAPCs could be
killed successfully in vivo following treatment with GCV
(14 days, 50 mg/kg) [26]. In this study, we assessed
whether administration of GCV to mice with HSV-TK
containing mOct4− BM-MAPCs present in and around a
glioblastoma (GL261) could also kill the glioblastoma
cells via a suicide killing bystander effect [9]. Hereby, it
is essential to assess the capacity of eGFP-fLuc-HSV-TK-
expressing and ihSPIO-labeled mOct4− BM-MAPCs to
distribute within and around the glioblastoma. We have
engrafted 5 × 105 mOct4− BM-MAPCs into the mousebrain, of which only a fraction (1 or 10 %) of the injected
cells was labeled with ihSPIO particles, as 3 × 105 cells
already generated extensive hypointense contrast (Fig. 3).
Evaluation of the grafted cells by MRI showed that when
10 % (Fig. 3b), but not 1 % (Fig. 3a) of the stem cells
were labeled with ihSPIO particles it was possible to fol-
low them by MRI as indicated by the hypointense signal.
One representative animal is shown in Fig. 3c.
Stereotactical injection of 5x105 mOct4− BM-MAPCs,
of which 10 % were ihSPIO labeled, into the striatum of
GL261 tumor bearing C57BL6/j mice was performed. For
this, GL261 tumors were allowed to expand for 14 days
after which MRI was performed to ascertain tumor
growth (Fig. 4 =d14). Subsequently, stem cells were
stereotactically injected and MRI and BLI were performed
on the following day (=d16) to ascertain stem cell location
in and around the tumor. PBS or GCV (50 mg/kg) admin-
istration commenced on day 16 and continued for 14 con-
secutive days (i.e. until d30 following GL261 tumor
induction). At d30 post GL261 injection, sham operated
animals and some PBS treated animals started to develop
grade 3 symptoms that were related to tumor growth, and
needed to be sacrificed. MRI and BLI were performed
weekly for the duration of the experiment for the assess-
ment of tumor growth and stem cell viability.
Figure 4e (lower rows) confirmed that 10 % labeled
stem cells could be tracked by MRI due to their ihSPIO
labeling.
Using T2*-weighted MR images, we were able to dem-
onstrate for all animals receiving 10 % labeled mOct4−
BM-MAPCs that the tumors contained and were
surrounded by ihSPIO-labeled mOct4− BM-MAPCs
from the first imaging time point post-engraftment (day
16 postinjection). Tumor volumes were determined from
T2-weighted MR images (Fig. 4e, lower row). Tumors
were present in all three groups of animals.
Fig. 2 In vivo assessment of mOct4− BM-MAPCs SPIO labeling. a Analysis of in vivo three-dimensional T2* MR images on day 2 and day 8 postinjection
showed hypointense voxel volume of the Endorem®- and ihSPIO-labeled mOct4− BM-MAPCs. b MRI data corresponded to the Masson’s trichrome
staining to locate the stem cells and a Prussian blue staining to stain for the presence of iron in the tissue. *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
0.0001. ihSPIO in-house superparamagnetic iron oxide, p.i. postinjection
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showed significantly smaller tumors after the end of
treatment when compared to sham and PBS-treated ani-
mals (Fig. 4a) However, we noticed some substantial
variability between individual animals.
While all sham-operated animals (n = 5) showed sub-
stantial tumor masses at the end of the treatment period
(day 30), some of the PBS-treated animals showed a sub-
stantially smaller tumor size compared to the rest (n =
4/12 PBS-treated animals; Fig. 4b and c). Among the
GCV-treated animals, all animals showed apparent delay
in tumor development. Fifteen out of 18 animals showeda significantly reduced tumor volume when compared to
sham and PBS-treated animals (<15 mm3). When con-
sidering our predefined criteria of ‘no tumor growth’
compared to the start of treatment (volume <5 mm3), 11
animals responded to treatment while 7 animals did
show at least some increase in tumor volume (Fig. 4b
and c). MRI analysis showed that sham-operated (n = 5),
nonresponding PBS-treated animals (n = 8) and GCV-
treated, nonresponding animals (n = 7) developed tu-
mors on day 30 after transplantation of the glioblastoma
cells that were not statistically different in size (Fig. 4b
and c). For all GCV-treated animals, BLI signal intensity
Fig. 3 In vivo suicide gene therapy using eGFP-fLuc-HSV-TK (+), ihSPIO-labeled mOct4− BM-MAPCs in a mouse glioblastoma model. a Hypointense
signal volume determination (three-dimensional T2* MRI) on 1 % labeled mOct4− BM-MAPCs did not show statistically significant differences between
stem cell injected animals (phosphate-buffered saline (PBS)/ganciclovir (GCV)) and sham-operated animals (SHAM) 1 day after surgery (day 16). At the
end of treatment (day 30), there was, however, a significant difference between sham-operated animals and GCV-treated animals (**p < 0.01) due to
the smaller tumor sizes in the GCV-treated group. In the sham-operated and PBS-treated group, tumor formation was present which is accompanied
with necrosis and bleedings when tumors grow over time. In contrast, the hypointense signal in the GCV-treated group, which did not
develop tumors, is mostly generated by remaining labeled mOct4− BM-MAPCs. b Hypointense signal volume determination (three-dimensional
T2* MRI) on 10 % labeled mOct4− BM-MAPCs showed statistically significant differences between stem cell injected animals (PBS/GCV) and
sham-operated animals 1 day after surgery (day 16). At the end of treatment (day 30), there was a statistically significant difference between
sham-operated and PBS-treated animals and between the PBS-treated and GCV-treated groups. *p < 0.05, **p < 0.01, ***p < 0.001. c MR images
of one representative animal stereotactically injected with 1 % or 10 % labeled mOct4− BM-MAPCs showed that the hypointense contrast,
delineated in red, generated by 10 % labeled mOct4− BM-MAPCs was more pronounced compared to 1 % labeled cells. SC stem cell
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BLI signal intensity was seen between responding and
nonresponding animals within the GCV- and PBS-treated
groups (data not shown). Furthermore, a few animals
injected with mOct4− BM-MAPCs and treated with PBS
also displayed a reduced tumor size (n = 4) at the end of
PBS administration (Fig. 4b and c), although the BLI signal
from the mOct4− BM-MAPCs did not change over time
(Fig. 4d and f). Imaging results were confirmed by hist-
ology (Fig. 4g and Additional file 1: Figure S1).
A number of animals were observed long term to de-
termine progression-free survival (Fig. 5). Progression-
free survival curves generated for sham-operatedanimals (n = 3) and PBS-treated animals (n = 6) were
comparable. From the GCV-treated animals, some (n = 3)
did not respond to treatment and showed a similar sur-
vival to the sham-operated and PBS-treated animals.
However, some GCV-treated (n = 4) and one animal
treated with PBS displayed a longer progression-free sur-
vival, with two animals of the GCV-treated group surviv-
ing long term (184 days) without any signs of tumor re-
growth (Fig. 5a). The median progression-free survival of
sham-operated animals (35 days) was significantly lower
compared to GCV responding animals (119.5 days) (p =
0.0101). Furthermore, histological analysis was performed
to confirm the data obtained in vivo. Masson’s trichrome
Fig. 4 (See legend on next page.)
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Fig. 4 MRI and BLI images of one representative animal for each group. a Animals from the ganciclovir (GCV)-treated group displayed significantly
smaller tumors at the end of GCV treatment compared to phosphate-buffered saline (PBS)-treated and sham-operated (SHAM) animals (*p < 0.05).
Some substantial variability was noticed, however, between individual animals so subgroup analysis was performed (green bar: mOct4-
BM-MAPC steretactical injection; red bar: treatment phase). b Representation of subgroup tumor development over time for sham-operated,
PBS- and GCV-treated animals. No statistically significant differences could be found on day 14 and 16 between the different groups (green bar:
mOct4- BM-MAPC steretactical injection; red bar: treatment phase). c Statistical analysis of the tumor volumes at the end of treatment (day 30)
showed a statistically significant difference in tumor size between GCV responding (n = 11) animals and sham-operated (n = 5)/PBS-treated
animals (n = 8). Furthermore, some GCV-treated animals (n = 7) did not respond to therapy whereas some PBS-treated (n = 4) animals also showed a
reduced tumor size at the end of treatment. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. d mOct4− BM-MAPC viability measurements showed a
reduced cell viability for the GCV but not the PBS treated group. *p < 0.05, ****p < 0.0001. e MR images of animals of different groups show a
comparable tumor growth prior to mOct4− BM-MAPC injection on T2-weighted coronal MR images (upper row for each group) whereas there
is little hypointense contrast visible on three-dimensional T2* MR images. In sham-operated animals this mild hypointense contrast was
maintained as tumors grew larger although some increase in the hypointense voxel volume, due to the development of necrosis and bleedings,
was observed. mOct4− BM-MAPC-injected animals (PBS and GCV) could be detected by three-dimensional T2* MRI (lower row for each group) on
day 1 after injection. For animals which developed tumors, the hypointense voxels got more dispersed over time as tumors grew whereas mice
responding to GCV treatment had little tumors where labeled mOct4− BM-MAPCs could still be detected at the end of GCV treatment. f BLI
measurements showed a persistence of the BLI signal in PBS-treated animals indicating survival of the mOct4− BM-MAPCs whereas GCV-treated
animals showed a decreased viability after GCV treatment. Sham operated animals were used as negative controls. g Histological overview
images of brain sections from the respective animals of each treatment group stained with trichrome staining. d Day
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explaining the hypointense signal in large tumors. Prus-
sian blue staining confirmed the presence of ihSPIO parti-
cles in and around the tumor most likely due to the
engrafted mOct4−BM-MAPCs. In small lesions, as seen in
the therapy responders, iron staining was more concen-
trated around the injection site in comparison to large tu-
mors as seen in nonresponders. Finally, Iba I staining for
the presence of activated microglia was performed which
showed remarkably few activated microglial cells inside
the tumor, although microglial activation was more pro-
nounced surrounding the tumor (Fig. 6 and Additional file
1: Figure S1). Quantitative comparison between the differ-
ent groups based on Iba I staining was difficult due to theFig. 5 Progression-free survival analysis. a A number of animals were obser
(n = 3; SHAM), phosphate-buffered saline (PBS)-treated (n = 6) and ganciclo
free survival curves whereas the animals that responded to GCV (n = 4) tre
size after treatment displayed a prolonged progression-free survival with tw
any sign of tumor re-growth. b T2-weighted MRI images showing tumor g
treatment groups. d Day, SC stem cellreduced lesion size in responding animals and apparently
higher cell densities (Additional file 1: Figure S1).
In summary, longitudinal in vivo MRI and BLI monitor-
ing confirmed that HSV-TK-expressing mOct4− BM-
MAPCs are able to suppress tumor growth after admin-
istration of GCV in the majority of the animals.
Unexpectedly, a small number of PBS-treated animals
that received mOct4− BM-MAPCs also showed reduced
tumor sizes.
Discussion
Although efforts have been made to ameliorate the prog-
nosis for glioblastoma patients, results have been limited
so far [35]; the translation of preclinical research toved for a progression-free survival analysis. Sham-operated animals
vir (GCV) (n = 3) unresponsive animals had comparable progression-
atment and one animal treated with PBS but with a reduced tumor
o animals of the GCV-treated group surviving for 184 days without
rowth evolution in one representative animal for each of the three
Fig. 6 Histological analysis of representative animals at the end of treatment. Animals were sacrificed at the end of treatment and brain sections
were stained using Massson’s Trichrome staining (top) for overall histological assessment, Iba1 staining (middle) for assessment of macrophage
activation inside and surrounding the tumor, and Prussian blue staining (bottom) as an iron staining of brain sections from all different treatment
groups, including examples from responding and nonresponding animals. See Additional file 1 (Figure S1) for further high-magnification images
and a more elaborate explanation regarding the observations made based on these staining. GCV ganciclovir, PBS phosphate-buffered saline,
SHAM sham-operated
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past years, suicide gene therapy has been investigated as a
new therapeutic approach [8]. Unfortunately, results ob-
tained in clinical trials have been disappointing, mainly
due to insufficient expression and poor intratumoral dis-
tribution of the viral vectors encoding for the suicide gene
[36]. Therefore, HSV-TK-expressing stem cells that are
able to track tumor cells [4–7, 9] have been considered as
vehicles for suicide gene delivery. Increasing emphasis on
noninvasive follow-up aims to better understand the fate
of stem cells in the preclinical phase [25, 37] with the ul-
timate aim of better translatability from mouse to man.
Tumor size, viability and location can be validated with
MRI, PET or BLI prior to stem cell injection, thus identi-
fying outliers earlier [25, 37]. Furthermore, the location
and viability of the stem cells prior to initiation of treat-
ment is crucial as this will greatly influence the outcome
of bystander suicide therapy. Moreover, individual animals
can be followed longitudinally, thus reducing the number
of animals needed, while additional information can be
obtained to better understand the dynamics of experimen-
tal glioblastoma treatment approaches. Outliers that are
based on experimental errors such as failure of correct cell
implantation can also be identified.
In this study, GL261 tumor bearing C57BL6/j mice re-
ceived 5 × 105 syngeneic eGFP-fLuc-HSV-TK-expressingand ihSPIO-labeled (1 % or 10 %) mOct4− BM-MAPCs
for longitudinal follow-up of suicide gene therapy in im-
munocompetent animals following in vitro and in vivo
feasibility studies for cell detection.
Hypointense signal volume determination (three-dimen-
sional T2* MRI) on 1 % labeled mOct4− BM-MAPCs did
not show statistically significant differences between stem
cell-injected animals (PBS/GCV) and sham-operated ani-
mals 1 day after surgery (day 16). However, at the end of
treatment (day 30), there was a significant difference be-
tween sham-operated animals and GCV-treated animals
due to the smaller tumor sizes in the GCV-treated group.
In the sham-operated and PBS-treated group, tumor for-
mation was present which was accompanied with necrosis
and bleedings when tumors grew over time. In contrast,
the hypointense MRI signal in the GCV-treated group,
which did not develop tumors, was mostly generated by
ihSPIO label, which remained present in the brain after
killing of the mOct4− BM-MAPCs.
MRI data showed that labeled mOct4− BM-MAPCs
were located in and in close proximity to the tumor
from 1 day postinjection for all animals. Therefore, treat-
ment was commenced on day 1 postinjection following
multimodal imaging (MRI/BLI). In the majority of GCV-
treated, but not PBS-treated, animals a significant differ-
ence was found in mOct4− BM-MAPC viability and
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confirmed the location of labeled mOct4− BM-MAPCs
around the tumor lesion for all animals, three GCV-
treated animals did not show delayed tumor growth for
unknown reasons. However, not only the majority of
GCV-treated animals but also some PBS-treated animals
showed a significant decrease in tumor size compared to
sham-operated animals. Although no direct experimen-
tal evidence could be provided in our study, one hypoth-
esis in the suicide gene therapy field is that the initial,
limited intratumoral killing of both stem cells and tumor
cells, caused by injection of the stem cells and the inhos-
pitable tumor microenvironment, generates the release
of immunostimulatory molecules [38–40]. This may
contribute to overcome immune suppression by the
tumor. Our results show, however, that all PBS-treated
animals displayed mOct4− BM-MAPC survival during
PBS administration as determined by BLI. This indicates
that the observed effect on tumor growth in the PBS-
treated group is probably not majorly influenced by
mOct4− BM-MAPC cell death. Another possible explan-
ation for the reduction of tumor growth could be the
immunomodulatory properties of MAPCs themselves
and their capability to exert both immune suppression
and immune stimulation [41], which might cause the
immune system to favor immune stimulation rather than
immune suppression in the tumor setting and thus con-
tribute to a therapeutic effect and a reduction in tumor
size. As this goes beyond the scope of our study, further
research is required to confirm this hypothesis. Independ-
ent of the possible immune stimulation of mOct4−BM-
MAPC engraftment, our studies demonstrate clearly that
adding GCV treatment augments killing of the glioblast-
oma, which is likely the result of the typical bystander kill-
ing effect, and could possibly be enhanced by additional
immune-stimulation. Furthermore, histological analysis
showed the presence of large blood vessels explaining the
hypointense signal in large tumors (Masson’s Trichrome)
and the presence of ihSPIO particles in and around the
tumor (Prussian blue staining). In smaller tumors, iron
staining was more concentrated to the injection site in
comparison to large tumors. Microglial cells were identi-
fied mostly at the tumor border, although areas of micro-
glial activation within the tumor tissue were also found.
However, no clear differences could be found between
sham-operated, PBS- and GCV-treated animals in micro-
glial activation status, which again stresses the need for fu-
ture studies focusing on immunological aspect of this
treatment model.
Conclusions
We have shown that suicide gene therapy using mOct4−
BM-MAPCs as cellular carriers is effective in reducing
the tumor size in the majority of the GCV-treatedanimals, resulting in a longer progression-free survival
compared to sham-operated animals. The treatment can
be guided and followed in vivo by MRI and BLI. Hereby,
MRI can be used to ascertain stem cell location prior to
treatment initiation and follow-up of tumor size. BLI
can be used to assess stem cell viability prior to and fol-
lowing treatment. Thus, outliers can be detected earlier,
GCV treatment can be initiated based on stem cell dis-
tribution rather than on empirical time points, and a
more thorough follow-up can be provided prior to and
following treatment of these animals. This will contrib-
ute to a rapid and efficient validation of stem cell-based
therapeutic approaches for glioblastoma and therefore to
a better understanding and optimization of a promising
therapeutic approach for glioblastoma patients.
Additional file
Additional file 1: Figure S1. High magnification images from brain
sections of representative animals for all groups and subgroups. Massson’s
Trichrome staining (top) of sham-operated and PBS-injected, control animals
showed very large tumors with some bleeding. Prussian blue (bottom)
staining was also performed, which indicated presence of iron (*) in PBS-
injected, control animals that did not respond to treatment. For these
animals, positive iron staining was seen both at the tumor border (left
Prussian blue staining) and inside the tumor mass (right Prussian blue
staining). GCV-treated responders showed high iron content as the cells
remained more localized around the much smaller tumor lesions. The
presence of high amounts of iron is an indication for the presence of
SPIO from engrafted, labeled stem cells. Finally, Iba1 staining (middle)
was performed which showed microglial activation in the GCV-treated
responding group. Microglial activation was also pronounced around
the tumor in sham-operated and PBS-injected, control animals. In general,
Prussian blue and Iba1 staining appears more intense in animals that
responded to treatment due to the small (former) lesion site. (TIFF 6465 kb)
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